This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.
In 2019, Seagen announced that it had initiated another trial of Tukysa – the HER2CLIMB-02 study – that will compare Tukysa to placebo in combination with Kadcyla (ado-trastuzumab emtansine) in
trastuzumab emtansine). ... Trastuzumab deruxtecan is central to Daiichi’s growth efforts, and is also a key drug for AZ’s cancer franchise.
Seattle is seeking approval for tucatinib in combination with Roche’s anti-HER2 antibody (trastuzumab) plus Xeloda (capecitabine). ... ado-trastuzumab emtansine).
Looking forward to this year and beyond, additional indications for Tecentriq and HER2-positive breast cancer antibody-drug conjugate Kadcyla (trastuzumab emtansine) will also help drive future growth, said Roche, although ... the latter is facing new
The US regulator has cleared the HER2 inhibitor drug – now known as Enhertu (trastuzumab deruxtecan) – for metastatic HER2-positive disease in patients who have previously been treated with two or more ... Perjeta (pertuzumab) and Kadcyla
The EMA has cleared Kadcyla (ado-trastuzumab emtansine) for the adjuvant or post-surgery treatment of adults with HER2-positive early breast cancer, who still have some residual signs of invasive ... cancer cells despite treatment before surgery with
More from news
Approximately 5 fully matching, plus 53 partially matching documents found.
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Roche already has a somewhat underperforming trastuzumab-based ADC in the form of Kadcyla (trastuzumab emtansine)
It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). . ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
trastuzumab emtansine), received its first EU approval. for HER2+ metastatic breast cancer patients who did not respond to Herceptin and/or taxane.
Roche’s Kadcyla (trastuzumab emtansine). the Committee stated that while it demonstrates relevant survival benefit, its use as second-line treatment of metastatic disease was considered not to be a priority
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
No results were found
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...